Roche acquires biotech company Inflazome for EUR 380m
September 22, 2020
The Swiss pharmaceutical group Roche is taking over the Irish biotech company Inflazome, the biotech company announced on Monday. Roche wants to pay EUR 380m to the Inflazome shareholders. The biotech company produces active ingredients against inflammatory diseases such as asthma. According to the Irish Times, payment marks a sevenfold return for VC investors, including Ireland’s Fountain Healthcare Partners as well as Forbion, Longitude Capital and Novartis Venture Fund, who have pumped EUR 55m into the business.
ⓘ This story was originally featured in our daily M&A Insights newsletter.